Roche Holding AG (ROG)’s MabThera medicine won the backing of the U.K.’s National Institute for Health and Clinical Excellence in new draft guidance on the treatment of people with advanced follicular lymphoma.
Research shows that adding the drug to a greater number of chemotherapy regimens, including chlorambucil, helps patients live longer and improves quality of life, the institute, known as NICE, said in an e-mailed statement today. NICE advises the state-run National Health Service on which therapies represent value for money. The agency will publish final guidance on MabThera next month.
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org